Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
- PMID: 18794097
- DOI: 10.1158/1078-0432.CCR-08-1046
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
Abstract
Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) and to characterize the relationship between LEP-ETU concentrations and the time course of neutropenia in cancer patients.
Experimental design: LEP-ETU was administered to 88 patients and 63 were evaluable for pharmacokinetic/pharmacodynamic (PK/PD) analysis following 1.5- and 3-h infusions every 3 weeks (q3w; dose range, 135-375 mg/m(2)). MTD was identified using a 3 + 3, up-and-down dose-finding algorithm. PK/PD modeling was done to describe the temporal relationship between paclitaxel concentrations and neutrophil count. Simulations assessed the influence of dose and schedule on neutropenia severity to help guide dose selection.
Results: The MTD of LEP-ETU was identified as 325 mg/m(2). DLTs occurring at 375 mg/m(2) consisted of febrile neutropenia and neuropathy. The C(max) and area under the plasma concentration-time curve of LEP-ETU were less than proportional with increasing dose. The PK/PD model showed that LEP-ETU inhibition of neutrophil proliferation was 9.1% per 10 mug/mL of total paclitaxel concentration. The incidence of grade 4 neutropenia increased from 33% to 42% across the dose range of 275 to 325 mg/m(2) q3w. For a dose of 110 mg/m(2) given weekly, grade 4 neutropenia was estimated to be 16% compared with 42% for the same total dose administered q3w.
Conclusions: LEP-ETU can be administered safely at higher doses than Taxol. Modeling and simulation studies predict that 325 mg/m(2) LEP-ETU q3w provides acceptable neutropenic events relative to those observed at 175 mg/m(2) Taxol q3w. A 275 mg/m(2) dose may offer an improved therapeutic index.
Similar articles
-
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.Eur J Cancer. 2004 Mar;40(5):681-8. doi: 10.1016/j.ejca.2003.11.027. Eur J Cancer. 2004. PMID: 15010068 Clinical Trial.
-
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.Cancer Chemother Pharmacol. 2006 Jun;57(6):727-35. doi: 10.1007/s00280-005-0112-6. Epub 2005 Oct 28. Cancer Chemother Pharmacol. 2006. PMID: 16261364 Clinical Trial.
-
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.Clin Cancer Res. 2003 Nov 1;9(14):5187-94. Clin Cancer Res. 2003. PMID: 14613998 Clinical Trial.
-
Paclitaxel pharmacokinetics and pharmacodynamics.Semin Oncol. 1995 Jun;22(3 Suppl 6):16-23. Semin Oncol. 1995. PMID: 7597430 Review.
-
Liposomal paclitaxel formulations.J Control Release. 2012 Nov 10;163(3):322-34. doi: 10.1016/j.jconrel.2012.09.006. Epub 2012 Sep 15. J Control Release. 2012. PMID: 22989535 Review.
Cited by
-
Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment.Asian J Pharm Sci. 2022 Nov;17(6):817-837. doi: 10.1016/j.ajps.2022.11.002. Epub 2022 Nov 17. Asian J Pharm Sci. 2022. PMID: 36415834 Free PMC article. Review.
-
Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.J Nanobiotechnology. 2022 May 18;20(1):233. doi: 10.1186/s12951-022-01431-8. J Nanobiotechnology. 2022. PMID: 35585597 Free PMC article.
-
Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications.Polymers (Basel). 2022 Feb 9;14(4):658. doi: 10.3390/polym14040658. Polymers (Basel). 2022. PMID: 35215570 Free PMC article. Review.
-
Bioactive nanotherapeutic trends to combat triple negative breast cancer.Bioact Mater. 2021 Mar 13;6(10):3269-3287. doi: 10.1016/j.bioactmat.2021.02.037. eCollection 2021 Oct. Bioact Mater. 2021. PMID: 33778204 Free PMC article. Review.
-
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.Int J Nanomedicine. 2020 Oct 22;15:8151-8166. doi: 10.2147/IJN.S272529. eCollection 2020. Int J Nanomedicine. 2020. PMID: 33132699 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous